TITLE

At-the-Market Financing Facility Secures ISCO $25M

PUB. DATE
December 2010
SOURCE
Bioworld Week;12/20/2010, Vol. 18 Issue 51, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that Apsire Capital Fund LLC agreed to purchase 333,333 shares from International Stem Cell Corp. (ISCO) and is granted a financing facility which allows Aspire to purchase up to 25 million dollars in equity capital over the next three years at ISCO's discretion.
ACCESSION #
56681362

 

Related Articles

  • At-the-Market Financing Facility Secures ISCO $25M. Shaffer, Catherine // BioWorld Today;12/14/2010, Vol. 21 Issue 240, p1 

    The article reports on Aspire Capital Fund LLC's purchase of shares of International Stem Cell Corp. The agreement covers a financing facility that will permit Aspire to acquire up to 25 million U.S. dollars in equity capital. Companies such as Bionovo Inc. and Dynavax Technologies Corp. have...

  • Cardica secures $10 million stock purchasing agreement.  // Medical Device Daily;12/17/2010, Vol. 14 Issue 244, p3 

    The article reports that Cardica in Redwood City, California, has secured a common stock purchase agreement with Aspire Capital Fund in Chicago, Illinois. Under the agreement, Cardica will regulate the timing and amount of any sales of its common stock to Aspire and each time that Cardica...

  • Financings Roundup.  // BioWorld Today;12/18/2012, Vol. 23 Issue 244, p5 

    This section offers news briefs on financing in the pharmaceutical biotechnology industry. A 32 million U.S. dollar Series A preferred stock financing was closed by Allakos Inc. A common stock purchase agreement has been signed by Cyclacel Pharmaceuticals Inc. with Aspire Capital Fund LLC. A...

  • Financings Roundup.  // BioWorld Today;10/24/2013, Vol. 24 Issue 205, p3 

    This section offers finance-related news briefs as of October 24, 2013. Adma Biologics Inc. closed its initial public offering of shares of common stock. Athersys Inc. placed an equity facility with Aspire Capital Fund LLC to replace a two-year agreement. Cormedix Inc. closed the sale of 150,000...

  • Financings Roundup.  // BioWorld Today;7/23/2010, Vol. 21 Issue 141, p6 

    This section offers news briefs on corporate financings including a 10 million U.S. dollar second tranche secured by Integrated Diagnostics of its 30 million U.S. dollar Series A financing, a memorandum of understanding entered into by International Stem Cell Corp. with German investment fund...

  • Financings Roundup.  // BioWorld Today;7/7/2009, Vol. 20 Issue 128, p3 

    The article reports on the $5 million investment commitment made by International Stem Cell Corp. in July 2009. As stated, the proceeds will be used for operations and working capital needs and to boost the company's scientific research. Details of the investment strategy are elaborated. Also...

  • Financings roundup.  // Medical Device Daily;5/6/2010, Vol. 14 Issue 87, p3 

    The article reports on the definitive agreement between International Stem Cell and Socius CG II for the purchase of non-convertible Series D preferred stock.

  • National HealthCare renews $75M credit line with BoA.  // Medical Device Daily;10/27/2011, Vol. 15 Issue 206, p3 

    This section offers news briefs on financing in the medical device industry, including the decision of National HealthCare to renew its one year 75 million U.S. dollar credit line agreement with the Bank of America (BoA), the 12 million U.S. dollar Series D investment completed by MedVentive...

  • Dynavax, Aspire enter $30M Stock Purchase Deal.  // Bioworld Week;9/27/2010, Vol. 18 Issue 39, p4 

    The article reports on the 30 million stock purchase deal between Dynavax Technologies Corp. and investor Aspire Capital Fund LLC with an initial investment of two million dollar in Berkeley, California.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics